Xiaofang Huo1,2, Agoston T Agoston3, Kerry B Dunbar1,2, Daisha J Cipher4, Xi Zhang1,2, Chunhua Yu1,2, Edaire Cheng1,5, Qiuyang Zhang1,2, Thai H Pham1,6, Uttam K Tambar7, Richard K Bruick7, David H Wang1,2,8, Robert D Odze3, Stuart J Spechler1,2,8, Rhonda F Souza1,2,8. 1. Esophageal Diseases Center, VA North Texas Health Care System and the University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2. Department of Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical Center, Dallas, Texas, USA. 3. Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 4. College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, Texas, USA. 5. Department of Pediatrics, Children's Medical Center and the University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6. Department of Surgery, VA North Texas Health Care System and the University of Texas Southwestern Medical Center, Dallas, Texas, USA. 7. Department of Biochemistry, University of Texas Southwestern Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 8. Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
OBJECTIVE: In an earlier study wherein we induced acute reflux by interrupting proton pump inhibitor (PPI) therapy in patients with reflux oesophagitis (RO) healed by PPIs, we refuted the traditional concept that RO develops as an acid burn. The present study explored our alternative hypothesis that RO results from reflux-stimulated production of pro-inflammatory molecules mediated by hypoxia-inducible factors (HIFs). DESIGN: Using oesophageal biopsies taken from patients in our earlier study at baseline and at 1 and 2 weeks off PPIs, we immunostained for HIF-1α, HIF-2α and phospho-p65, and measured pro-inflammatory molecule mRNAs. We exposed human oesophageal squamous cell lines to acidic bile salts, and evaluated effects on HIF activation, p65 function, pro-inflammatory molecule production and immune cell migration. RESULTS: In patient biopsies, increased immunostaining for HIF-2α and phospho-p65, and increased pro-inflammatory molecule mRNA levels were seen when RO redeveloped 1 or 2 weeks after stopping PPIs. In oesophageal cells, exposure to acidic bile salts increased intracellular reactive oxygen species, which decreased prolyl hydroxylase function and stabilised HIF-2α, causing a p65-dependent increase in pro-inflammatory molecules; conditioned media from these cells increased T cell migration rates. HIF-2α inhibition by small hairpin RNA or selective small molecule antagonist blocked the increases in pro-inflammatory molecule expression and T cell migration induced by acidic bile salts. CONCLUSIONS: In patients developing RO, increases in oesophageal HIF-2α correlate with increased pro-inflammatory molecule expression. In oesophageal epithelial cells, acidic bile salts stabilise HIF-2α, which mediates expression of pro-inflammatory molecules. HIF-2α appears to have a role in RO pathogenesis. TRIAL REGISTRATION NUMBER: NCT01733810; Results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: In an earlier study wherein we induced acute reflux by interrupting proton pump inhibitor (PPI) therapy in patients with reflux oesophagitis (RO) healed by PPIs, we refuted the traditional concept that RO develops as an acid burn. The present study explored our alternative hypothesis that RO results from reflux-stimulated production of pro-inflammatory molecules mediated by hypoxia-inducible factors (HIFs). DESIGN: Using oesophageal biopsies taken from patients in our earlier study at baseline and at 1 and 2 weeks off PPIs, we immunostained for HIF-1α, HIF-2α and phospho-p65, and measured pro-inflammatory molecule mRNAs. We exposed human oesophageal squamous cell lines to acidic bile salts, and evaluated effects on HIF activation, p65 function, pro-inflammatory molecule production and immune cell migration. RESULTS: In patient biopsies, increased immunostaining for HIF-2α and phospho-p65, and increased pro-inflammatory molecule mRNA levels were seen when RO redeveloped 1 or 2 weeks after stopping PPIs. In oesophageal cells, exposure to acidic bile salts increased intracellular reactive oxygen species, which decreased prolyl hydroxylase function and stabilised HIF-2α, causing a p65-dependent increase in pro-inflammatory molecules; conditioned media from these cells increased T cell migration rates. HIF-2α inhibition by small hairpin RNA or selective small molecule antagonist blocked the increases in pro-inflammatory molecule expression and T cell migration induced by acidic bile salts. CONCLUSIONS: In patients developing RO, increases in oesophageal HIF-2α correlate with increased pro-inflammatory molecule expression. In oesophageal epithelial cells, acidic bile salts stabilise HIF-2α, which mediates expression of pro-inflammatory molecules. HIF-2α appears to have a role in RO pathogenesis. TRIAL REGISTRATION NUMBER: NCT01733810; Results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Thorsten Cramer; Yuji Yamanishi; Björn E Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S Firestein; Hans Peter Gerber; Napoleone Ferrara; Randall S Johnson Journal: Cell Date: 2003-03-07 Impact factor: 41.582
Authors: Xiang Xue; Sadeesh Ramakrishnan; Erik Anderson; Matthew Taylor; Ellen M Zimmermann; Jason R Spence; Sha Huang; Joel K Greenson; Yatrik M Shah Journal: Gastroenterology Date: 2013-07-13 Impact factor: 22.682
Authors: Xiaofang Huo; Xi Zhang; Chunhua Yu; Edaire Cheng; Qiuyang Zhang; Kerry B Dunbar; Thai H Pham; John P Lynch; David H Wang; Robert S Bresalier; Stuart J Spechler; Rhonda F Souza Journal: Gut Date: 2017-04-25 Impact factor: 23.059
Authors: Joanne C Masterson; Kathryn A Biette; Juliet A Hammer; Nathalie Nguyen; Kelley E Capocelli; Bejan J Saeedi; Rachel F Harris; Shahan D Fernando; Lindsay B Hosford; Caleb J Kelly; Eric L Campbell; Stefan F Ehrentraut; Faria N Ahmed; Hiroshi Nakagawa; James J Lee; Eóin N McNamee; Louise E Glover; Sean P Colgan; Glenn T Furuta Journal: J Clin Invest Date: 2019-07-02 Impact factor: 14.808
Authors: Rhonda F Souza; Liela Bayeh; Stuart J Spechler; Uttam K Tambar; Richard K Bruick Journal: Curr Opin Pharmacol Date: 2017-11-05 Impact factor: 5.547
Authors: Michael B Cook; Matthew J Barnett; Cathryn H Bock; Amanda J Cross; Phyllis J Goodman; Gary E Goodman; Christopher A Haiman; Kay-Tee Khaw; Marjorie L McCullough; Christine C Newton; Marie-Christine Boutron-Ruault; Eiliv Lund; Martin Rutegård; Mark D Thornquist; Michael Spriggs; Carol Giffen; Neal D Freedman; Troy Kemp; Candyce H Kroenke; Loïc Le Marchand; Jin Young Park; Michael Simon; Lynne R Wilkens; Ligia Pinto; Allan Hildesheim; Peter T Campbell Journal: Gut Date: 2018-08-18 Impact factor: 23.059
Authors: Stuart J Spechler; Juanita L Merchant; Timothy C Wang; Parakrama Chandrasoma; James G Fox; Robert M Genta; James R Goldenring; Yoku Hayakawa; Ernst J Kuipers; Pauline K Lund; Frank McKeon; Jason C Mills; Robert D Odze; Richard M Peek; Thai Pham; Jianwen Que; Anil K Rustgi; Nicholas J Shaheen; Ramesh A Shivdasani; Rhonda F Souza; Peter Storz; Andrea Todisco; David H Wang; Nicholas A Wright Journal: Gastroenterology Date: 2017-06-03 Impact factor: 33.883